Short-chain fatty acid inhibitors of histone deacetylases: Promising anticancer therapeutics?

Current Cancer Drug Targets

Volumn 3, Issue 3, 2003, Pages 219-236

  Chen, James S ^a   Faller, Douglas V ^a   Spanjaard, Remco A ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; APICIDIN; ARYLBUTYRIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; BUTYRIC ACID; CARBOXYCINNAMIC ACID BISHYDROXAMIDE; CYCLIN D; HEXAMETHYLENEBISACETAMIDE; HISTONE DEACETYLASE INHIBITOR; MS 27275; OXAMFLATIN; PROTEIN P21; PROTEIN P27; SHORT CHAIN FATTY ACID; TETRAPEPTIDE; TRAPOXIN; TRICHOSTATIC ACID; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ADVERSE DRUG REACTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL CYCLE; CELL DIFFERENTIATION; CHROMATIN; CLINICAL TRIAL; DNA REPLICATION; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE SILENCING; GENETIC TRANSCRIPTION; GENOTOXICITY; HUMAN; ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL CYCLE; ENZYME INHIBITORS; FATTY ACIDS, VOLATILE; HISTONE DEACETYLASES; HUMANS; NEOPLASMS;

EID: 0038555374     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009033481994     Document Type: Review

References (211)

1. Pardee, A. B.; Campisi J.; Croy, R. G. Differences in Growth Regulation of Normal and Tumor Cells. Ann. NY Acad. Sci. 1982, 397, 121-129.
2. Cooper, G. M. Oncogenes; Jones and Bartlett Publishers: Boston, 1990.
3. Dang, C. V.; Semenza G. L. Oncogenic Alterations of Metabolism. Trends Biochem. Sci. 1999, 24, 68-72.
4. Bouchard, C.; Staller, P.; Eilers, M. Control of Cell Proliferation by Myc. Trends Cell Biol. 1998, 8, 202-206.
5. Laird, A. D.; Shalloway, D. Oncoprotein Signalling and Mitosis. Cell Signal. 1997, 9, 249-255.
6. Shapiro, G. I.; Harper, J. W. Anticancer Drug Targets: Cell Cycle and Checkpoint Control. J. Clin. Invest. 1999, 104, 1645-1653.
7. Pardee, A. B. G1 Events and Regulation of Cell Proliferation. Science 1989, 246, 603-608.
8. King, K. L.; Cidlowski, J. A. Cell Cycle Regulation and Apoptosis. Annu. Rev. Physiol. 1998, 60, 601-617.
9. Guo, M.; Hay, B. A. Cell Proliferation and Apoptosis. Curr. Opin. Cell Biol. 1999, 11, 745-752.
10. Blagosklonny, M. V. A Node between Proliferation, Apoptosis, and Growth Arrest. Bioessays 1999, 21, 704-709.
11. O'Keefe, E. J.; Pledger, W. J. A Model of Cell Cycle Control: Sequential Events Regulated by Growth Factors. Mol. Cell Endocrinol. 1983, 31, 167-186.
12. Sherr, C. J. The Pezcoller Lecture: Cancer Cell Cycles Revisited. Cancer Res. 2000, 60, 3689-3695.
13. Hunter, T. Cooperation between Oncogenes. Cell 1991, 64, 249-270.
14. Varmus, H.; Bishop, J. M (Eds.): Biochemical Mechanisms of Oncogene Activity: Proteins Encoded By Oncogenes. Oxford: Oxford University Press; 1986.
15. Hunter, T.; Pines, J. Cyclins and Cancer. Cell 1991, 66, 1071-1074.
16. Nilsson, I, Hoffmann I. Cell Cycle Regulation by the Cdc25 Phosphatase Family. Prog. Cell Cycle Res. 2000, 4, 107-114.
17. Noble, M. E.; Endicott, J. A.; Brown, N. R.; Johnson, L. N. The Cyclin Box Fold: Protein Recognition in Cell-Cycle and Transcription Control. Trends Biochem. Sci. 1997, 22, 482-487.
18. Geng, Y.; Whoriskey, W.; Park, M. Y.; Bronson, R. T.; Medema, R. H.; Li, T.; Weinberg, R. A.; Sicinski, P. Rescue of Cyclin D1 Deficiency by Knockin Cyclin E. Cell 1999, 97, 767-777.
19. Koff, A.; Giordano, A.; Desai, D.; Yamashita, K.; Harpe, R J. W.; Elledge, S.; Nishimoto, T.; Morgan, D. O.; Franza, B. R.; Roberts, J. M. Formation and activation of a Cyclin E-Cdk2 Complex During the G1 Phase of the Human Cell Cycle. Science 1992, 257, 1689-1694.
20. Matsushime, H.; Quelle, D. E.; Shurtleff, S. A.; Shibuya, M.; Sherr, C. J.; Kato, J. Y. D-Type Cyclin-Dependent Kinase Activity in Mammalian Cells. Mol. Cell Biol. 1994, 14, 2066-2076.
21. Sherr, C. J.; Matsushime, H.; Roussel, M. F. Regulation of CYL/Cyclin D Genes by Colony-Stimulating Factor 1. CIBA Found. Symp. 1992, 170, 209-219.
22. Matsushime, H.; Roussel, M. F.; Ashmun, R. A.; Sherr, C. J. Colony-Stimulating Factor I Regulates Novel Cyclins During the G1 Phase of the Cell Cycle. Cell 1991, 65, 701-713.
23. Chellappan, S. P.; Hiebert, S.; Mudryj, M.; Horowitz, J. M.; Nevins, J. R. The E2F Transcription Factor Is a Cellular Target for the RB Protein. Cell 1991, 65, 1053-1061.
24. Bandara, L. R.; Adamczewski, J. P.; Hunt, T.; La Thangue, N. B. Cyclin a and the Retinoblastoma Gene Product Complex with a Common Transcription Factor. Nature 1991, 352, 249-251.
25. Goodrich, D. W.; Wang, N. P.; Qian, Y. W.; Lee, E. Y.; Lee, W. H. The Retinoblastoma Gene Product Regulates Progression through the G I Phase of the Cell Cycle. Cell 1991, 67, 293-302.
26. Ewen, M. E.; Sluss, H. K.; Sherr, C. J.; Matsushime, H.; Kato, J.; Livingston, D. M. Functional Interactions of the Retinoblastoma Protein with Mammalian D-Type Cyclins. Cell 1993, 73, 487-497.
27. Nevins, J. R.; Chellappan, S. P.; Mudryj, M.; Hiebert, S.; Devoto, S.; Horowitz, J.; Hunter, T.; Pines, J. E2F Transcription Factor is a Target for the RB Protein and the Cyclin a Protein. Cold Spring Harb Symp. Quant. Biol. 1991, 56, 157-162.
28. Lin, B. T.; Gruenwald, S.; Morla, A O.; Lee, W. H.; Wang, J. Y. Retinoblastoma Cancer Suppressor Gene Product is a Substrate of the Cell Cycle Regulator Cdc2 Kinase. EMBO J. 1991, 10, 857-864.
29. Sherr, C. J.; Roberts, J. M. CDK Inhibitors: Positive and Negative Regulators of G1-Phase Progression. Genes Dev. 1999, 13, 1501-1512.
30. Kamb, A.; Gruis, N. A.; Weaver-Feldhaus, J.; Liu, Q.; Harshman, K.; Tavtigian, S. V.; Stockert, E.; Day, R. S. 3rd.; Johnson, B. E.; Skolnick, M. H. A Cell Cycle Regulator Potentially involved in Genesis of Many Tumor Types. Science 1994, 264, 436-440.
31. Kamb, A.; Shattuck-Eidens, D.; Eeles, R.; Liu, Q.; Gruis, N. A.; Ding, W.; Hussey, C.; Tran, T.; Miki, Y.; Weaver-Feldhaus, J.; McClure, M.; Aitken, J.F.; Anderson, D.E.; Bergman, W.; Frants, R.; Goldgar, D.E.; Green, A.; MacLennan, R.; Martin, N.G.; Meyer, L.J.; Youl, P.; Zone, J.J.; Skolnick, M.H.; Cannon-Albright, L.A. Analysis of the P16 Gene (CDKN2) as a Candidate for the Chromosome 9p Melanoma Susceptibility Locus. Nat. Genet. 1994, 8, 23-26.
32. Lee, C. T.; Capodieci, P.; Osman, I.; Fazzari, M.; Ferrara, J.; Scher, H. I.; Cordon-Cardo, C. Overexpression of the Cyclin-Dependent Kinase Inhibitor p16 is associated with Tumor Recurrence in Human Prostate Cancer. Clin. Cancer Res. 1999, 5, 977-983.
33. Chin, L.; Pomerantz, J.; Depinho, R. A. The INK4a/aRF Tumor Suppressor: One Gene - Two Products - Two Pathways. Trends Biochem. Sci. 1998, 23, 291-296.
34. Pomerantz, J.; Schreiber-Agus, N.; Liegeois, N. J.; Silverman, A.; Alland, L.; Chin, L.; Potes, J.; Chen, K.; Orlow, I.; Lee, H. W.; Cordon-Cardo, C.; Depinho, R. A. The lnk4a Tumor Suppressor Gene Product, p19arf, interacts with MDM2 and Neutralizes MDM2's inhibition of p53. Cell 1998, 92, 713-723.
35. Vogelstein, B.; Kinzler, K. W. p53 Function and Dysfunction. Cell 1992, 70, 523-526.
36. Harper, J. W.; Adami, G. R.; Wei, N.; Keyomarsi, K.; Elledge, S. J. The p21 Cdk-Interacting Protein Cip1 is a Potent Inhibitor of G1 Cyclin- Dependent Kinases. Cell 1993, 75, 805-816.
37. Halevy, O.; Novitch, B. G.; Spicer, D. B.; Skapek, S. X.; Rhee, J.; Hannon, G. J.; Beach, D.; Lassar, A. B. Correlation of Terminal Cell Cycle Arrest of Skeletal Muscle with induction of p21 by MyoD. Science 1995, 267, 1018-1021.
38. Liu, M.; Iavarone, A.; Freedman, L. P. Transcriptional Activation of the Human p21(WaF1/CIP1) Gene by Retinoic acid Receptor. Correlation with Retinoid Induction of U937 Cell Differentiation. J. Biol. Chem. 1996, 271, 31723-31728.
39. Liu, M.; Lee, M. H.; Cohen, M.; Bommakanti, M.; Freedman, L. P. Transcriptional Activation of the Cdk Inhibitor p21 by Vitamin D3 Leads To the induced Differentiation of the Myelomonocytic Cell Line U937. Genes Dev. 1996, 10, 142-153.
40. Missero, C.; Calautti, E.; Eckner, R.; Chin, J.; Tsai, L. H.; Livingston, D. M.; Dotto, G. P. Involvement of the Cell-Cycle Inhibitor Cip1/WaF1 and the Ela-Associated P300 Protein in Terminal Differentiation. Proc. Natl. Acad. Sci. USA 1995, 92, 5451-5455.
41. Steinman, R. A.; Hoffman, B.; Iro, A.; Guillouf, C.; Liebermann, D. A.; El-Houseini, M. E. Induction of p21 (WAF-1/CIP1) During Differentiation. Oncogene 1994, 9, 3389-3396.
42. Polyak, K.; Kato, J. Y.; Solomon, M. J.; Sherr, C. J.; Massague, J.; Roberts, J. M.; Koff, A. p27Kip1, a Cyclin-Cdk Inhibitor, Links Transforming Growth Factor-Beta and Contact inhibition to Cell Cycle Arrest. Genes Dev. 1994, 8, 9-22.
43. Coats, S.; Flanagan, W. M.; Nourse, J.; Roberts, J. M. Requirement of p27Kip1 for Restriction Point Control of the Fibroblast Cell Cycle. Science 1996, 272, 877-880.
44. Toyoshima, H.; Hunter, T. p27, a Novel Inhibitor of G1 Cyclin-Cdk Protein Kinase activity, is Related to p21. Cell 1994, 78, 67-74.
45. Polyak, K.; Lee, M. H.; Erdjument-Bromage, H.; Koff, A.; Roberts, J. M.; Tempst, P.; Massague, J. Cloning of p27Kip1, a Cyclin-Dependent Kinase Inhibitor and a Potential Mediator of Extracellular Antimitogenic Signals. Cell 1994, 78, 59-66.
46. Shirane, M.; Harumiya, Y.; Ishida, N.; Hirai, A.; Miyamoto, C.; Hatakeyama, S.; Nakayama, K.; Kitagawa, M. Down-Regulation of p27(Kip1) by Two Mechanisms, Ubiquitin-Mediated Degradation and Proteolytic Processing. J. Biol. Chem. 1999, 274, 13886-13893.
47. Morgan, D. O. Cyclin-Dependent Kinases: Engines, Clocks, and Microprocessors. Annu. Rev. Cell Dev. Biol. 1997, 13, 261-291.
48. Hartwell, L. H.; Weinert, T. A. Checkpoints: Controls that Ensure the Order of Cell Cycle Events. Science 1989, 246, 629-634.
49. Murray, A. W. Creative Blocks: Cell-Cycle Checkpoints and Feedback Controls. Nature 1992, 359, 599-604.
50. Russell, P. Checkpoints on the Road to Mitosis. Trends Biochem. Sci. 1998, 23, 399-402.
51. Johnston, G. C.; Pringle, J. R.; Hartwell, L. H. Coordination of Growth with Cell Division in the Yeast Saccharomyces Cerevisiae. Exp. Cell Res. 1977, 105, 79-98.
52. O'Connell, M. J, Walworth, N. C, Carr, A. M. The G2-Phase DNa-Damage Checkpoint. Trends Cell Biol. 2000, 10, 296-303.
53. Dasso, M.; Newport, J. W. Completion of DNa Replication is Monitored by a Feedback System that Controls the Initiation of Mitosis in Vitro: Studies in Xenopus. Cell 1990, 61, 811-823.
54. Kelly, T. J.; Brown, G. W. Regulation of Chromosome Replication. Annu. Rev. Biochem. 2000, 69, 829-880.
55. Vogelstein, B.; Lane, D.; Levine, A. J. Surfing the p53 Network. Nature 2000, 408, 307-310.
56. Xiong, Y.; Hannon, G. J.; Zhang, H.; Casso, D.; Kobayashi, R.; Beach, D. p21 is a Universal Inhibitor of Cyclin Kinases. Nature 1993, 366, 701-704.
57. Guo, N.; Faller, D. V.; Vaziri, C. The p53 -independent S- Phase Checkpoint Elicited by Benzo[alpha]pyrene is Chkl-Mediated and Caffeine-Sensitive. Cell Growth Differ. 2002, 13, 77-86.
58. Hartwell, L. Defects in a Cell Cycle Checkpoint May Be Responsible for the Genomic Instability of Cancer Cells. Cell 1992, 71, 543-546.
59. Kitazono, A.; Matsumoto, T. "Isogaba Maware": Quality Control of Genome DNA by Checkpoints. Bioessays 1998, 20, 391-399.
60. Chellappan, S.; Kraus, V. B.; Kroger, B.; Munger, K.; Howley, P. M.; Phelps, W. C.; Nevins, J. R. Adenovirus Ela, Simian Virus 40 Tumor Antigen, and Human Papillomavirus E7 Protein Share the Capacity to Disrupt the Interaction between Transcription Factor E2F and the Retinoblastoma Gene Product. Proc. Natl. Acad. Sci. USA 1992, 89, 4549-4553.
61. Bagchi, S.; Raychaudhuri, P.; Nevins, J. R. Adenovirus E1a Proteins Can Dissociate Heteromeric Complexes Involving the E2F Transcription Factor: a Novel Mechanism for E1a Trans-Activation. Cell 1990, 62, 659-669.
62. Bagchi, S.; Weinmann, R.; Raychaudhuri, P. The Retinoblastoma Protein Copurifies with E2F-I, an E1a-Regulated Inhibitor of the Transcription Factor E2F. Cell 1991, 65, 1063-1072.
63. Bandara, L. R.; La Thangue, N. B. Adenovirus E1a Prevents the Retinoblastoma Gene Product From Complexing with a Cellular Transcription Factor. Nature 1991, 351, 494-497.
64. Archer, S. Y.; Meng, S.; Shei, A.; Hodin, R. A. p21(WAF1) is Required for Butyrate-Mediated Growth inhibition of Human Colon Cancer Cells. Proc. Natl. Acad. Sci. USA 1998, 95, 6791-6796.
65. Bouchard, M.; Giannakopoulos, S.; Wang, E. H.; Tanese, N.; Schneider, R. J. Hepatitis B Virus Hbx Protein Activation of Cyclin a-Cyclin-Dependent Kinase 2 Complexes and G1 Transit via a Src Kinase Pathway. J. Virol. 2001, 75, 4247-4257.
66. Wang, J.; Chenivesse, X.; Henglein, B.; Brechot, C. Hepatitis B Virus integration in a Cyclin a Gene in a Hepatocellular Carcinoma. Nature 1990, 343, 555-557.
67. Wang, J.; Zindy, F.; Chenivesse, X.; Lamas, E.; Henglein, B.; Brechot, C. Modification of Cyclin a Expression by Hepatitis B Virus DNA integration in a Hepatocellular Carcinoma. Oncogene 1992, 7, 1653-1656.
68. Muller, H.; Helin, K. The E2F Transcription Factors: Key Regulators of Cell Proliferation. Biochim. Biophys. Acta 2000, 1470, M1-M12.
69. Prives, C. Signaling to p53: Breaking the MDM2-p53 Circuit. Cell 1998, 95, 5-8.
70. Giaccia, A. J.; Kastan, M. B. The Complexity of p53 Modulation: Emerging Patterns From Divergent Signals. Genes Dev. 1998, 12, 2973-2983.
71. Kohn, K. W. Molecular Interaction Map of the Mammalian Cell Cycle Control and DNA Repair Systems. Mol. Biol. Cell 1999, 10, 2703-2734.
72. Kornberg, R. D.; Lorch, Y. Twenty-Five Years of the Nucleosome, Fundamental Particle of the Eukaryote Chromosome. Cell 1999, 98, 285-294.
73. Fuks, F.; Burgers, W. A.; Brehm, A.; Hughes-Davies, L.; Kouzarides, T. DNA Methyltransferase Dnmt1 associates with Histone Deacetylase Activity. Nat. Genet. 2000, 24, 88-91.
74. Taunton, J.; Hassig, C. A.; Schreiber, S. L. A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p. Science 1996, 272, 408-411.
75. Rundlett, S. E.; Carmen, A. A.; Kobayashi, R.; Bavykin, S.; Turner, B. M.; Grunstein, M. HDAI and RPD3 are Members of Distinct Yeast Histone Deacetylase Complexes that Regulate Silencing and Transcription. Proc. Natl. Acad. Sci. USA 1996, 93, 14503-14508.
76. Carmen, A. A.; Rundlett, S. E.; Grunstein, M. HDA1 and HDA3 are Components of a Yeast Histone Deacetylase (HDA) Complex. J. Biol. Chem. 1996, 271, 15837-15844.
77. Imai, S.; Armstrong, C. M.; Kaeberlein.; M, Guarente, L. Transcriptional Silencing and Longevity Protein Sir2 is an NaD- Dependent Histone Deacetylase. Nature 2000, 403, 795-800.
78. Emiliani, S.; Fischle, W.; Van Lint, C.; Al-Abed, Y.; Verdin, E. Characterization of a Human RpD3 Ortholog, HDAC3. Proc. Natl. Acad Sci. USA 1998, 95, 2795-2800.
79. Grozinger, C. M.; Hassig, C. A.; Schreiber, S. L. Three Proteins Define a Class of Human Histone Deacetylases Related to Yeast HDA1p. Proc. Natl. Acad. Sci. USA 1999, 96, 4868-4873.
80. Magnaghi-Jaulin, L.; Groisman, R.; Naguibneva, I.; Robin, P.; Lorain, S.; Le Villain, J. P.; Troalen, F.; Trouche, D.; Harel-Bellan, A. Retinoblastoma Protein Represses Transcription by Recruiting a Histone Deacetylase. Nature 1998, 391, 601-605.
81. Brehm, A.; Miska, E. A.; Mccance, D. J.; Reid, J. L.; Bannister, A. J.; Kouzarides, T. Retinoblastoma Protein Recruits Histone Deacetylase to Repress Transcription. Nature 1998, 391, 597-601.
82. Brehm, A.; Kouzarides, T. Retinoblastoma Protein Meets Chromatin. Trends Biochem. Sci. 1999, 24, 142-145.
83. Bouzahzah, B.; Fu, M.; Iavarone, A.; Factor, V. M.; Thorgeirsson, S. S.; Pestell, R. G. Transforming Growth Factor-Beta1 Recruits Histone Deacetylase 1 to a p130 Repressor Complex in Transgenic Mice in Vivo. Cancer Res. 2000, 60, 4531-4537.
84. Laherty, C. D.; Yang, W. M.; Sun, J. M.; Davie, J. R.; Seto, E.; Eisenman, R. N. Histone Deacetylases Associated with the Msin3 Corepressor Mediate Mad Transcriptional Repression. Cell 1997, 89, 349-356.
85. Nagy, L.; Kao, H. Y.; Chakravarti, D.; Lin, R. J.; Hassig, C. A.; Ayer, D. E.; Schreiber, S. L.; Evans, R. M. Nuclear Receptor Repression Mediated by a Complex Containing SMRT, Msin3a, and Histone Deacetylase. Cell 1997, 89, 373-380.
86. Murphy, M.; Ahn, J.; Walker, K. K.; Hoffman, W. H.; Evans, R. M.; Levine, A. J.; George, D. L. Transcriptional Repression by Wild-Type p53 Utilizes Histone Deacetylases, Mediated by Interaction with Msin3a. Genes Dev. 1999, 13, 2490-2501.
87. Imai, T.; Yamauchi, M.; Seki, N.; Sugawara, T.; Saito, T.; Matsuda, Y.; Ito, H.; Nagase, T.; Nomura, N.; Hori, T. Identification and Characterization of a New Gene Physically Linked to the ATM Gene. Genome Res. 1996, 6, 439-447.
88. Zhao, J.; Dynlacht, B.; Imai, T.; Hori, T.; Harlow, E. Expression of NPAT, a Novel Substrate of Cyclin E-CDK2, Promotes S- Phase Entry. Genes Dev. 1998, 12, 456-461.
89. Zhao, J.; Kennedy, B. K.; Lawrence, B. D.; Barbie, D. A.; Matera, A. G.; Fletcher, J. A.; Harlow, E. NPAT Links Cyclin E-Cdk2 to the Regulation of Replication-Dependent Histone Gene Transcription. Genes Dev. 2000, 14, 2283-2297.
90. Lagger, G.; O'Carroll, D.; Rembold, M.;, Khier, H.; Tischler, J.; Weitzer, G.; Schuettengruber, B.; Hauser, C.; Brunmeir, R.; Jenuwein, T.; Seiser, C. Essential Function of Histone Deacetylase 1 in Proliferation Control and CDK Inhibitor Repression. EMBO J 2002, 21, 2672-2681.
91. Sartorelli, V.; Puri, P. L.; Hamamori, Y.; Ogryzko, V.; Chung, G.; Nakatani, Y.; Wang, J. Y.; Kedes, L. Acetylation of Myod Directed by PCaF is Necessary for the Execution of the Muscle Program. Mol. Cell. 1999, 4, 725-734.
92. Martinez-Balbas, M. A.; Bauer, U. M.; Nielsen, S. J.; Brehm, A.; Kouzarides, T. Regulation of E2F1 Activity by Acetylation. EMBO J. 2000, 19, 662-671.
93. Marzio, G.; Wagener, C.; Gutierrez, M. I.; Cartwright, P.; Helin, K.; Giacca, M. E2F Family Members are Differentially Regulated by Reversible Acetylation. J. Biol. Chem. 2000, 275, 10887-10892.
94. Gu, W.; Roeder, R. G. Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain. Cell 1997, 90, 595-606.
95. Yang, X. J.; Ogryzko, V. V.; Nishikawa, J.; Howard, B. H.; Nakatani, Y. A p300/CBP-Associated Factor that Competes with the Adenoviral Oncoprotein E1a. Nature 1996, 382, 319-324.
96. Finzer, P.; Kuntzen, C.; Soto, U.; Hausen, H. Z.; Rosl, F. Inhibitors of Histone Deacetylase Arrest Cell Cycle and induce Apoptosis in Cervical Carcinoma Cells Circumventing Human Papillomavirus Oncogene Expression. Oncogene 2001, 20, 4768-4776.
97. Hassig, C. A.; Tong, J. K.; Fleischer, T. C.; Owa, T.; Grable, P. G.; Ayer, D. E.; Schreiber, S. L. A Role for Histone Deacetylase Activity in HDAC1-Mediated Transcriptional Repression. Proc. Natl. Acad. Sci. USA 1998, 95, 3519-3524.
98. Archer, S. Y.; Hodin, R. A. Histone Acetylation and Cancer. Curr. Opin. Genet. Dev. 1999, 9, 171-174.
99. Petrij, F.; Giles, R. H.; Dauwerse, H. G.; Saris, J. J.; Hennekam, R. C.; Masuno, M.; Tommerup, N.; van Ommen, G. J.; Goodman, R. H.; Peters, D. J. M.; Breuning, M. H. Rubinstein-Taybi Syndrome Caused by Mutations in the Transcriptional Co-Activator CBP. Nature 1995, 376, 348-351.
100. Redner, R. L.; Wang, J.; Liu, J. M. Chromatin Remodeling and Leukemia: New Therapeutic Paradigms. Blood 1999, 94, 417-428.
101. Lin, R. L.; Nagy, L.; Inoue, S.; Shao, W.; Miller, W. H.; Evans, R. M. Role of the Histone Deacetylase Complex in acute Promyelocytic Leukaemia. Nature 1998, 391, 811-814.
102. Mckenna, N. J.; O'Malley, B. W. Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators. Cell 2002, 108, 465-474.
103. Huang, M. E.; Ye, Y. C.; Chen, S. R.; Chai, J. R.; Lu, J. X.; Zhoa, L.; Gu, L. J.; Wang, Z. Y. Use of all-Trans Retinoic acid in the Treatment of Acute Promyelocytic Leukemia. Blood 1988, 72, 567-572.
104. Warrell, R. P., Jr.; Frankel, S. R.; Miller, W. H, Jr.; Scheinberg, D. A.; Itri, L. M.; Hittelman, W. N.; Vyas, R.; Andreeff, M.; Tafuri, A.; Jakubowski, A.; Gabrilove, J.; Gordon, M.S.; Dmitrovsky, E. Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-Trans-Retinoic Acid). N. Engl. J. Med. 1991, 324, 1385-1393.
105. He, L. Z.; Guidez, F.; Tribioli, C.; Peruzzi, D.; Ruthardt, M.; Zelent, A.; Pandolfi, P. P. Distinct Interactions of PML-RARalpha and PLZF-RARalpha with Co-Repressors Determine Differential Responses to RA in APL. Nat. Genet. 1998, 18, 126-135.
106. Warrell, R. P.; He, L.-Z.; Richon, V.; Calleja, E.; Pandolfi, P. P. Therapeutic Targeting of Transcription in Acute Promyelocytic Leukemia by Use of an Inhibitor of Histone Deacetylase. J. Natl. Cancer Inst. 1998, 90, 1621-1625.
107. Ferrara, F. F.; Fazi, F.; Bianchini, A.; Padula, F.; Gelmetti, V.; Minucci, S.; Mancini, M.; Pelicci, P. G.; Lo Coco, F.; Nervi, C. Histone Deacetylase-Targeted Treatment Restores Retinoic Acid Signaling and Differentiation in Acute Myeloid Leukemia. Cancer Res. 2001, 61, 2-7.
108. Demary, K.; Wong, L.; Spanjaard, R. A. Effects of Retinoic Acid and Sodium Butyrate on Gene Expression, Histone Acetylation, and inhibition of Proliferation in Melanoma Cells. Cancer Lett. 2001, 163, 103-107.
109. Velazquez, O. C.; Lederer, H. M.; Rombeau, J. L. Butyrate and the Colonocyte: Production, Absorption, Metabolism, and Therapeutic Implications. Adv. Exp. Med. Biol. 1997, 427, 123-134.
110. Boffa, L. C.; Lupton, J. R.; Mariani, M. R.; Ceppi, M.; Newmark, H. L.; Scalmati, A.; Lipkin, M. Modulation of Colonic Epithelial Cell Proliferation, Histone Acetylation, and Luminal Short Chain Fatty Acids by Variation of Dietary Fiber (Wheat Bran) in Rats. Cancer Res. 1992, 52, 5906-5912.
111. Cummings, J. H.; Pomare, E. W.; Branch, W. J.; Naylor, C. P.; Macfarlane, G. T. Short Chain Fatty Acids in Human Large intestine, Portal, Hepatic and Venous Blood. Gut 1987, 28, 1221-1227.
112. Macfarlane, G. T.; Gibson, G. R. Microbiological Aspects of the Production of Short-Chain Fatty Acids in the Large Bowel. In: Physiological And Clinical Aspects Of Short-Chain Fatty Acids. Pp. 87-105. Cambridge: Cambridge University Press; 1995: 87-105.
113. Sakata, T. Influence of Short Chain Fatty Acids on intestinal Growth and Functions. Adv. Exp. Med. Biol. 1997, 427, 191-199.
114. Scheppach, W.; Bartram, P.; Richter, A.; Richter, F.; Liepold, H.; Dusel, G.; Hofstetter, G.; Ruthlein, J.; Kasper, H. Effect of Short-Chain Fatty Acids on the Human Colonic Mucosa in Vitro. J. Parenter. Enter. Nutr. 1992, 16, 43-48.
115. Pouillart, P. R. Role of Butyric Acid and Its Derivatives in the Treatment of Colorectal Cancer and Hemoglobinopathies. Life Sci. 1998, 63, 1739-1760.
116. Kruh, J. Effects of Sodium Butyrate, a New Pharmacological Agent, on Cells in Culture. Mol. Cell. Biochem. 1982, 42, 65-82.
117. Wintersberger, E.; Mudrak, I.; Wintersberger, U. Butyrate inhibits Mouse Fibroblasts at a Control Point in the G1 Phase. J. Cell. Biochem. 1983, 21, 239-247.
118. Kruh, J.; Defer, N.; Tichonicky, L. Molecular and Cellular action of Butyrate. C R Seances Soc. Biol. Fil. 1992, 186, 12-25.
119. Hague, A.; Elder, D. J.; Hicks, D. J.; Paraskeva, C. Apoptosis in Colorectal Tumour Cells: Induction by the Short Chain Fatty Acids Butyrate, Propionate and Acetate and by the Bile Salt Deoxycholate. Int. J. Cancer. 1995, 60, 400-406.
120. Hague, A.; Paraskeva, C. The Short-Chain Fatty Acid Butyrate Induces Apoptosis in Colorectal Tumour Cell Lines. Eur. J. Cancer Prev. 1995, 4, 359-364.
121. Heerdt, B. G.; Houston, M. A.; Augenlicht, L. H. Potentiation by Specific Short-Chain Fatty Acids of Differentiation and Apoptosis in Human Colonic Carcinoma Cell Lines. Cancer Res. 1994, 54, 3288-3293.
122. Hague, A.; Manning, A. M.; Hanlon, K. A.; Huschtscha, L. I.; Hart, D.; Paraskeva, C. Sodium Butyrate Induces Apoptosis in Human Colonic Tumour Cell Lines in a p53 -Independent Pathway: Implications for the Possible Role of Dietary Fibre in the Prevention of Large-Bowel Cancer. Int. J Cancer. 1993, 55, 498-505.
123. Guilbaud, N. F.; Gas, N.; Dupont, M. A.; Valette, A. Effects of Differentiation-Inducing Agents on Maturation of Human MCF-7 Breast Cancer Cells. J. Cell Physiol. 1990, 145, 162-172.
124. Graham, K. A.; Buick, R. N. Sodium Butyrate Induces Differentiation in Breast Cancer Cell Lines Expressing the Estrogen Receptor. J. Cell Physiol. 1988, 136, 60-71.
125. Ryan, M. P.; Borenfreund, E.; Higgins, P. J. Butyrate- Induced Cytoarchitectural Reorganization of Mallory Body-Containing Rat Hepatic Tumor Cells. J. Natl. Cancer Inst. 1987, 79, 555-567.
126. Velazquez O. C.; Rombeau J. L. Butyrate: Potential Role in Colon Cancer Prevention and Treatment. Adv. Exp. Med. Biol. 1997, 427, 169-181.
127. Sowa, Y.; Sakai, T: Butyrate as a Model for "Gene- Regulating Chemoprevention and Chemotherapy". Biofactors 2000, 12, 283-287.
128. Sealy, L.; Chalkley, R. The Effect of Sodium Butyrate on Histone Modification. Cell 1978, 14, 115-121.
129. Mariadason, J. M.; Corner, G. A.; Augenlicht, L. H. Genetic Reprogramming in Pathways of Colonic Cell Maturation Induced by Short Chain Fatty Acids: Comparison with Trichostatin a, Sulindac, and Curcumin and Implications for Chemoprevention of Colon Cancer. Cancer Res. 2000, 60, 4561-4572.
130. Perrine, S. P.; Greene, M. F.; Faller, D. V. Delay in the Fetal Globin Switch in Infants of Diabetic Mothers. N. Engl. J. Med. 1985, 312, 334-338.
131. Perrine, S. P.; Miller, B. A.; Greene, M. F.; Cohen, R. A.; Cook, N.; Shackleton, C.; Faller, D. V. Butryic Acid Analogues Augment Gamma Globin Gene Expression in Neonatal Erythroid Progenitors. Biochem. Biophys. Res. Commun. 1987, 148, 694-700.
132. Perrine, S.; Kan, Y. W.; Greene, M. F.; Rubin, E.; Cooper, S.; Cohen, R.; Roman, C.; Rudolph, A.; Faller, D. V. Inhibition of Fetal Globin Gene Switching in Vivo in Human and Ovine Fetuses. Prog. Clin. Biol. Res. 1987, 251, 545-554.
133. Perrine, S. P.; Rudolph, A.; Faller, D. V.; Roman, C.; Cohen, R. A.; Chen, S. J.; Kan, Y. W. Butyrate infusions in the Ovine Fetus Delay the Biologic Clock for Globin Gene Switching. Proc. Natl. Acad. Sci. USA 1988, 85, 8540-8542.
134. Perrine, S. P.; Greene, M. F.; Cohen, R. A.; Faller, D. V. A Physiological Delay in Human Fetal Hemoglobin Switching is Associated with Specific Globin DNA Hypomethylation. FEBS Lett. 1988, 228, 139-143.
135. Perrine, S. P.; Miller, B. A.; Papayannopoulou, T.; Faller, D. V.; Rudolph, A. M.; Vichinsky, E.; Hurst, D.; Kan, Y. W. Butyrate Analogues Modulate Globin Gene Expression in Human and Ovine Erythroid Cells. Prog. Clin. Biol. Res. 1989, 316B, 341-350.
136. Perrine, S. P.; Swerdlow, P.; Faller, D. V.; Qin, G.; Rudolph, A. M.; Reczek, J.; Kan, Y. W. Butyric Acid Modulates Developmental Globin Gene Switching in Man and Sheep. Adv. Exp. Med. Biol. 1989, 271, 177-183.
137. Perrine, S. P.; Faller, D. V.; Swerdlow, P.; Miller, B. A.; Bank, A.; Sytkowski, A. J.; Reczek, J.; Rudolph, A. M.; Kan, Y. W. Stopping the Biologic Clock for Globin Gene Switching. Ann. NY Acad. Sci. 1990, 612, 134-140.
138. Perrine, S. P.; Faller, D. V. Butyrate-Induced ReActivation of the Fetal Globin Genes: a Molecular Treatment for the Beta-Hemoglobinopathies. Experientia 1993, 49, 133-137.
139. Perrine, S. P.; Ginder, G. D.; Faller, D. V.; Dover, G. H.; Ikuta, T.; Witkowska, H. E.; Cai, S. P.; Vichinsky, E. P.; Olivieri, N. F. A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the Beta-Globin Disorders. N. Engl. J. Med. 1993, 328, 81-86.
140. Perrine, S. P.; Olivieri, N. F.; Faller, D. V.; Vichinsky, E. P.; Dover, G. J.; Ginder, G. D. Butyrate Derivatives. New Agents for Stimulating Fetal Globin Production in the Beta-Globin Disorders. Am. J. Pediatr. Hematol. Oncol. 1994, 16, 67-71.
141. Perrine, S. P.; Miller, B. A.; Faller, D. V.; Cohen, R. A.; Vichinsky, E. P.; Hurst, D.; Lubin, B. H.; Papayannopoulou, T. Sodium Butyrate Enhances Fetal Globin Gene Expression in Erythroid Progenitors of Patients with Hb SS and Beta Thalassemia. Blood 1989, 74, 454-459.
142. Faller, D. V.; Perrine, S. P. Butyrate in the Treatment of Sickle Cell Disease and Beta-Thalassemia. Curr. Opin. Hematol. 1995, 2, 109-117.
143. Mentzer, S. J.; Fingeroth, J.; Reilly, J. J.; Perrine, S. P.; Faller, D. V. Arginine Butyrate-Induced Susceptibility to Ganciclovir in an Epstein-Barr-Virus-Associated Lymphoma. Blood Cells Mol. Dis. 1998, 24, 114-123.
144. Faller, D. V.; Mentzer, S. J.; Perrine, S. P. Induction of the Epstein-Barr Virus Thymidine Kinase Gene with Concomitant Nucleoside antivirals as a Therapeutic Strategy for Epstein-Barr Virus-Associated Malignancies. Curr. Opin. Oncol. 2001, 13, 360-367.
145. Mentzer, S. J.; Perrine, S. P.; Faller, D. V. Epstein-Barr Virus Post-Transplant Lymphoproliferative Disease and Virus-Specific Therapy: Pharmacological Re-Activation of Viral Target Genes with arginine Butyrate. Transplant. Infect. Dis. 2001, 3, 177-185.
146. Krishna, S.; Brown, N.; Faller, D. V.; Spanjaard, R. A. Differential Effects of Short Chain Fatty Acids on Head and Neck Squamous Carcinoma Cells. The Laryngoscope 2002, 112, 645-650.
147. Boosalis, M. S.; Ikuta, T.; Pace, B. S.; Da Fonseca, S.; White, G. L.; Faller, D. V.; Perrine, S. P. Abrogation of IL-3 Requirements and Stimulation of Hematopoietic Cell Proliferation in Vitro and in Vivo by Carboxylic Acids. Blood Cells Mol. Dis. 1997, 23.
148. Pace, B. S.; White, G. L.; Dover, G. J.; Boosalis, M. S.; Faller, D. V.; Perrine, S. P. Short-Chain Fatty Acid Derivatives Induce Fetal Globin Expression and Erythropoiesis in Vivo. Blood 2002, 100, 4640-4648.
149. Ikuta, T.; Kan, Y. W.; Swerdlow, P. S.; Faller, D. V.; Perrine, S. P. Alterations in Protein-DNA Interactions in the Gamma-Globin Gene Promoter in Response to Butyrate Therapy. Blood 1998, 92, 2924-2933.
150. Ikuta, T.; Atweh, G.; Boosalis, V.; White, G. L.; Da Fonseca, S.; Boosalis, M.; Faller, D. V.; Perrine, S. P. Cellular and Molecular Effects of a Pulse Butyrate Regimen and New Inducers of Globin Gene Expression and Hematopoiesis. Ann. NY Acad. Sci. 1998, 850, 87-99.
151. Boosalis, M. S.; Bandyopadhyay, R.; Bresnick, E. H.; Pace, B. S.; Van Demark, K.; Zhang, B.; Faller, D. V.; Perrine, S. P. Short-Chain Fatty Acid Derivatives Stimulate Cell Proliferation and Induce STAT-5 Activation. Blood 2001, 97, 3259-3267.
152. Yoshida, M.; Horinouchi, S.; Beppu, T. Trichostatin a and Trapoxin: Novel Chemical Probes for the Role of Histone Acetylation in Chromatin Structure and Function. Bioessays 1995, 17, 423-430.
153. Yoshida, M.; Beppu, T. Reversible Arrest of Proliferation of Rat 3Y1 Fibroblasts in Both the G1 and G2 Phases by Trichostatin A. Exp. Cell Res. 1988, 177, 122-131.
154. Richon, V. M.; Emiliani, S.; Verdin, E.; Webb, Y.; Breslow, R.; Rifkind, R. A.; Marks, P. A. A Class of Hybrid Polar Inducers of Transformed Cell Differentiation Inhibits Histone Deacetylases. Proc. Natl. Acad. Sci. USA 1998, 95, 3003-3007.
155. Richon, V. M.; Webb, Y.; Merger, R.; Sheppard, T.; Jursic, B.; Ngo, L.; Civoli, F.; Breslow, R.; Rifkind, R. A.; Marks, P. A. Second Generation Hybrid Polar Compounds are Potent Inducers of Transformed Cell Differentiation. Proc. Natl. Acad. Sci. USA 1996, 93, 5705-5708.
156. Saito, A.; Yamashita, T.; Mariko, Y.; Nosaka, Y.; Tsuchiya, K.; Ando, T.; Suzuki, T.; Tsuruo, T.; Nakanishi, O. A Synthetic Inhibitor of Histone Deacetylase, MS-27-275, with Marked in Vivo Antitumor Activity against Human Tumors. Proc. Natl. Acad. Sci. USA 1999, 96, 4592-4597.
157. Darkin-Rattray, S. J.; Gurnett, A. M.; Myers, R. W.; Dulski, P. M.; Crumley, T. M.; Allocco, J. J.; Cannova, C.; Meinke, P. T.; Colletti, S. L.; Bednarek, M. A.; Singh, S. B.; Goetz, M. A.; Dombrowski, A. W.; Polishook, J. D.; Schmatz, D. M. Apicidin: a Novel Antiprotozoal Agent that Inhibits Parasite Histone Deacetylase. Proc. Natl. Acad. Sci. USA 1996, 93, 13143-13147.
158. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a Histone Deacetylase Homologue Bound to the TSA and SAHA Inhibitors. Nature 1999, 401, 188-193.
159. Kim, Y. B.; Lee, K. H.; Sugita, K.; Yoshida, M.; Horinouchi, S. Oxamflatin is a Novel antitumor Compound that Inhibits Mammalian Histone Deacetylase. Oncogene 1999, 18, 2461-2470.
160. Nakanishi, O.; Baba, M.; Saito, A.; Yamashita, T.; Sato, W.; Abe, H.; Fukazawa, N.; Suzuki, T.; Sato, S.; Naito, M.; Tsuruo, T. Potentiation of the antitumor Activity by a Novel Quinoline Compound, MS-209, in Multidrug-Resistant Solid Tumor Cell Lines. Oncol. Res. 1997, 9, 61-69.
161. Suzuki, T.; Ando, T.; Tsuchiya, K.; Fukazawa, N.; Saito, A.; Mariko, Y.; Yamashita, T.; Nakanishi, O. Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide Derivatives. J. Med. Chem. 1999, 42, 3001-3003.
162. Saunders, N.; Dicker, A.; Popa, C.; Jones, S.; Dahler, A. Histone Deacetylase Inhibitors as Potential Anti-Skin Cancer Agents. Cancer Res. 1999, 59, 399-404.
163. Vaziri, C.; Stice, L.; Faller, D. V. Butyrate-Induced G1 Arrest Results From p21-independent Disruption of Retinoblastoma Protein-Mediated Signals. Cell Growth Differ. 1998, 9, 465-474.
164. Lee, R. J.; Albanese, C.; Fu, M.; D'Amico, M.; Lin, B.; Watanabe, G.; Haines, G. K., 3rd.; Siegel, P. M.; Hung, M. C.; Yarden, Y.; Horowitz, J. M.; Muller, W. J.; Pestell, R. G. Cyclin D1 is Required for Transformation by Activated Neu and is Induced through an E2F7-Dependent Signaling Pathway. Mol. Cell Biol. 2000, 20, 672-683.
165. Doetzlhofer, A.; Rotheneder, H.; Lagger, G.; Koranda, M.; Kurtev, V.; Brosch, G.; Wintersberger, E.; geiser, C. Histone Deacetylase 1 Can Repress Transcription by Binding to Sp1. Mol. Cell Biol. 1999, 19, 5504-5511.
166. Gorospe, M.; Shack, S.; Guyton, K. Z.; Samid, D.; Holbrook, N. J. Up-Regulation and Functional Role of p21Waf1/Cip1 During Growth Arrest of Human Breast Carcinoma MCF-7 Cells by Phenylacetate. Cell Growth Differ. 1996, 7, 1609-1615.
167. Muto, A.; Kizaki, M.; Yamato, K.; Kawai, Y.; Kamata- Matsushita, M.; Ueno, H.; Ohguchi, M.; Nishihara, T.; Koeffier, H. P.; Ikeda, Y. 1,25-Dihydroxyvitamin D3 Induces Differentiation of a Retinoic Acid-Resistant Acute Promyelocytic Leukemia Cell Line (UF-1) Associated with Expression of p21(WAF1/CIP1) and p27(KIP1). Blood 1999, 93, 2225-2233.
168. Lavelle, D.; Chen, Y. H.; Hankewych, M.; Desimone, J. Inhibition of
169. Stein, G. S.; Baserga, R.; Giordano, A.; Denhardt, D. T. (Eds.): The Molecular Basis of Cell Cycle And Growth Control, 1 Edn. New York: Wiley-Liss; 1999.
170. Lloyd, R. V.; Erickson, L. A.; Jin, L, Kulig, E.; Qian, X.; Cheville, J. C.; Scheithauer, B. W. p27kip1: a Multifunctional Cyclin-Dependent Kinase Inhibitor with Prognostic Significance in Human Cancers. Am. J. Pathol. 1999, 154, 313-323.
171. Tsihlias, J.; Kapusta, L.; Slingerland, J. The Prognostic Significance of altered Cyclin-Dependent Kinase Inhibitors in Human Cancer. Annu. Rev. Med. 1999, 50, 401-423.
172. Deng, C, Zhang, P, Harper, J. W, Elledge, S. J, Leder, P. Mice Lacking p21cip1/WAF1 Undergo Normal Development, but are Defective in G1 Checkpoint Control. Cell 1995, 82, 675-684.
173. Fero, M. L.; Rivkin, M.; Tasch, M.; Porter, P.; Carow, C. E.; Firpo, E.; Polyak, K.; Tsai, L. H.; Broudy, V.; Perlmutter, R. M.; Kaushansky, K.; Roberts, J. M. A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in P27(Kip1)-Deficient Mice. Cell 1996, 85, 733-744.
174. Kiyokawa, H.; Kineman, R. D.; Manova-Todorova, K. O.; Soares, V. C.; Hoffman, E. S.; Ono, M.; Khanam, D.; Hayday, A. C.; Frohman, L. A.; Koff, A. Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27(Kip1). Cell 1996, 85, 721-732.
175. Nakayama, K.; Ishida, N.; Shirane, M.; Inomata, A.; Inoue, T.; Shishido, N.; Horii, I.; Loh, D. Y. Mice Lacking P27(Kipl) Display increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors. Cell 1996, 85, 707-720.
176. Richon, V. M.; Sandhoff, T. W.; Rifkind, R. A.; Marks, P. A. Histone Deacetylase Inhibitor Selectively Induces p21waf1 Expression and Gene-Associated Histone Acetylation. Proc. Natl. Acad. Sci. USA 2000, 97, 10014-10019.
177. Sambucetti, L. C.; Fischer, D. D.; Zabludoff, S.; Kwon, P. O.; Chamberlin, H.; Trogani, N.; Xu, H.; Cohen, D. Histone Deacetylase inhibition Selectively Alters the Activity and Expression of Cell Cycle Proteins Leading to Specific Chromatin Acetylation and antiproliferative Effects. J. Biol. Chem. 1999, 274, 34940-34947.
178. Wharton, W.; Savell, J.; Cress, W. D.; Seto, E.; Pledger, W. J. Inhibition of Mitogenesis in Balb/C-3T3 Cells by Trichostatin A. Multiple Alterations in the Induction and Activation of Cyclin-Dependent Kinase Complexes. J. Biol. Chem. 2000, 275, 33981-33987.
179. Finzer, P.; Kuntzen, C.; Soto, U.; Zur Hausen, H.; Rosl, F. Inhibitors of Histone Deacetylase Arrest Cell Cycle and Induce Apoptosis in Cervical Carcinoma Cells Circumventing Human Papillomavirus Oncogene Expression. Oncogene 2001, 20, 4768-4776.
180. Van De Mark, K.; Chen, J. S.; Steliou, K.; Perrine, S. P.; Faller, D. V. Alpha-Lipoic Acid Induces p27(Kip1)-Dependent Cell Cycle Arrest in Non-Transformed Cell Lines and Apoptosis in Tumor Cell Lines. J. Cell Physiol. 2003, 194, 325-340.
181. Craig, C.; Wersto, R.; Kim, M.; Ohri, E.; Li, Z.; Katayose, D.; Lee, S. J.; Trepel, J.; Cowan, K.; Seth, P. A Recombinant adenovirus Expressing p27Kip1 Induces Cell Cycle Arrest and Loss of Cyclin-Cdk Activity in Human Breast Cancer Cells. Oncogene 1997, 14, 2283-2289.
182. Pili, R.; Kruszewski, M. P.; Hager, B. W.; Lantz, J.; Carducci, M. A. Combination of Phenylbutyrate and 13-Cis Retinoic Acid Inhibits Prostate Tumor Growth and Angiogenesis. Cancer Res. 2001, 61, 1477-1485.
183. Siu, L. L.; Von Hoff, D. D.; Rephaeli, A.; Izbicka, E.; Cerna, C.; Gomez, L.; Rowinsky, E. K.; Eckhardt, S. G. Activity of Pivaloyloxymethyl Butyrate, a Novel anticancer Agent, on Primary Human Tumor Colony-Forming Units. Invest. New Drugs 1998, 16, 113-119.
184. Solomon, L. Z.; Jennings, A. M.; Sharpe, P.; Cooper, A. J.; Malone, P. S. Effects of Short-Chain Fatty Acids on Primary Urothelial Cells in Culture: Implications for intravesical Use in Enterocystoplasties. J. Lab. Clin. Med. 1998, 132, 279-283.
185. Soldatenkov, V. A.; Prasad, S.; Voloshin, Y.; Dritschilo, A. Sodium Butyrate Induces Apoptosis and accumulation of Ubiquitinated Proteins in Human Breast Carcinoma Cells. Cell Death Differ. 1998, 5, 307-312.
186. Dyson, J. E.; Daniel, J.; Surrey, C. R. The Effect of Sodium Butyrate on the Growth Characteristics of Human Cervix Tumour Cells. Br. J. Cancer 1992, 65, 803-808.
187. Salminen, A.; Tapiola, T.; Korhonen, P.; Suuronen, T. Neuronal Apoptosis Induced by Histone Deacetylase Inhibitors. Brain Res. Mol. Brain Res. 1998, 61, 203-206.
188. Prasad, K. N.; Sinha, P. K. Effect of Sodium Butyrate on Mammalian Cells in Culture: a Review. In Vitro 1976, 12, 125-132.
189. Mcbain, J. A.; Eastman, A.; Nobel, C. S.; Mueller, G. C. Apoptotic Death in adenocarcinoma Cell Lines Induced by Butyrate and Other Histone Deacetylase Inhibitors. Biochem. Pharmacol. 1997, 53, 1357-1368.
190. Schwartz, B.; Avivi-Green, C.; Polak-Charcon, S. Sodium Butyrate Induces Retinoblastoma Protein Dephosphorylation, p16 Expression and Growth Arrest of Colon Cancer Cells. Mol. Cell. Biochem. 1998, 188, 21-30.
191. Giardina, C.; Boulares, H.; Inan, M. S. NSAIDs and Butyrate Sensitize a Human Colorectal Cancer Cell Line to TNF-alpha and Fas Ligation: the Role of Reactive Oxygen Species. Biochim. Biophys. Acta 1999, 1448, 425-438.
192. Siavoshian, S.; Segain, J. P.; Kornprobst, M.; Bonnet, C.; Cherbut, C.; Galmiche, J. P.; Blottiere, H. M. Butyrate and Trichostatin A Effects on the Proliferation/Differentiation of Human intestinal Epithelial Cells: Induction of Cyclin D3 and p21 Expression. Gut 2000, 46, 507-514.
193. Tsao, D.; Shi, Z. R.; Wong, A.; Kim, Y. S. Effect of Sodium Butyrate on Carcinoembryonic Antigen Production by Human Colonic Adenocarcinoma Cells in Culture. Cancer Res. 1983, 43,1217-1222.
194. Kim, Y. S.; Tsao, D.; Siddiqui, B.; Whitehead, J. S.; Arnstein, P.; Bennett, J.; Hicks, J. Effects of Sodium Butyrate and Dimethylsulfoxide on Biochemical Properties of Human Colon Cancer Cells. Cancer 1980, 45, 1185-1192.
195. Ryan, M. P.; Higgins, P. J. Cytoarchitecture of Kirsten Sarcoma Virus-Transformed Rat Kidney Fibroblasts: Butyrate-Induced Reorganization within the Actin Microfilament Network. J. Cell Physiol. 1988, 137, 25-34.
196. Koyama, N.; Koschmieder, S.; Tyagi, S.; Nurnberger, H.; Wagner, S.; Bocker, U.; Hoelzer, D.; Gerhard, O. O.; Kalina, U. Differential Effects of Histone Deacetylase Inhibitors on Interleukin-18 Gene Expression in Myeloid Cells. Biochem. Biophys. Res. Commun. 2002, 292, 937-943.
197. Rabizadeh, E.; Bairey, O.; Aviram, A.; Ben-Dror, I.; Shaklai, M.; Zimra, Y. Doxorubicin and a Butyric Acid Derivative Effectively Reduce Levels of BCL-2 Protein in the Cells of Chronic Lymphocytic Leukemia Patient. Eur. J. Haematol. 2001, 66, 263-271.
198. Maeda, T.; Towatari, M.; Kosugi, H.; Saito, H. Up- Regulation of Costimulatory/Adhesion Molecules by Histone Deacetylase Inhibitors in Acute Myeloid Leukemia Cells. Blood 2000, 96, 3847-3856.
199. Bernhard, D.; Ausserlechner, M. J.; Tonko, M.; Loffler, M.; Hartmann, B. L.; Csordas, A.; Kofler, R. Apoptosis Induced by the Histone Deacetylase Inhibitor Sodium Butyrate in Human Leukemic Lymphoblasts. FASEB J. 1999, 13, 1991-2001.
200. Januszewicz, E.; Rabizadah, E.; Novogrodsky, A.; Shaklai, M. Butyric Acid: Inhibition of Non-Leukemic and Chronic Myeloid Leukemia Granulocyte Macrophage Clonal Growth. Med. Oncol. Tumor Pharmacother. 1988, 5, 259-263.
201. Cioe, L.; Mcnab, A.; Hubbell, H. R.; Meo, P.; Curtis, P.; Rovera, G. Differential Expression of the Globin Genes in Human Leukemia K562(S) Cells Induced to Differentiate by Hemin or Butyric Acid. Cancer Res. 1981, 41, 237-243.
202. Terao, Y.; Nishida, J.; Horiuchi, S.; Rong, F.; Ueoka, Y.; Matsuda, T.; Kato, H.; Furugen, Y.; Yoshida, K.; Kato, K.; Wake, N. Sodium Butyrate Induces Growth Arrest and Senescence-Like Phenotypes in Gynecologic Cancer Cells. Int. J. Cancer 2001, 94, 257-267.
203. Krupitza, G.; Grill, S.; Harant, H.; Hulla, W.; Szekeres, T.; Huber, H.; Dittrich, C. Genes Related to Growth and invasiveness are Repressed by Sodium Butyrate in Ovarian Carcinoma Cells. Br. J. Cancer 1996, 73, 433-438.
204. Langdon, S. P.; Hawkes, M. M.; Hay, F. G.; Lawrie, S. S.; Schol, D. J.; Hilgers, J.; Leonard, R. C.; Smyth, J. F. Effect of Sodium Butyrate and Other Differentiation Inducers on Poorly Differentiated Human Ovarian Adenocarcinoma Cell Lines. Cancer Res. 1988, 48, 6161-6165.
205. Simon, B.; Merchant, J. L.; Eissele, R.; Kohler, K.; Arnold, R. Transient Transcriptional Activation of Gastrin During Sodium Butyrate-Induced Differentiation of Islet Cells. Regul. Pept. 1997, 70, 143-148.
206. Tuch, B. E.; Madrid, J. C. Development of Fetal Sheep Pancreas after Transplantation into Athymic Mice. Cell Transplant. 1996, 5, 483-489.
207. Rashid, S. F.; Moore, J. S.; Walker, E.; Driver, P. M.; Engel, J.; Edwards, C. E.; Brown, G.; Uskokovic, M. R.; Campbell, M. J. Synergistic Growth inhibition of Prostate Cancer Cells by 1 Alpha, 25-Dihydroxyvitamin D(3) and Its 19-Nor-Hexafluoride Analogs in Combination with Either Sodium Butyrate or Trichostatin A. Oncogene 2001, 20, 1860-1872.
208. Maier, S.; Reich, E.; Martin, R.; Bachem, M.; Altug, V.; Hautmann, R. E.; Gschwend, J. E. Tributyrin Induces Differentiation Growth Arrest and Apoptosis in androgen-Sensitive and androgen-Resistant Human Prostate Cancer Cell Lines. Int. J. Cancer 2000, 88, 245-251.
209. Carducci, M. A.; Nelson, J. B.; Chan-Tack, K. M.; Ayyagari, S. R.; Sweatt, W. H.; Campbell, P. A.; Nelson, W. G.; Simons, J. W. Phenylbutyrate Induces Apoptosis in Human Prostate Cancer and is More Potent than Phenylacetate. Clin. Cancer Res. 1996, 2, 379-387.
210. Gleave, M. E.; Sato, N.; Sadar, M.; Yago, V.; Bruchovsky, N.; Sullivan, L. Butyrate Analogue, Isobutyramide, Inhibits Tumor Growth and Time to androgen-independent Progression in the Human Prostate LnCaP Tumor Model. J. Cell. Biochem. 1998, 69, 271-281.
211. Walls, R.; Thibault, A.; Liu, L.; Wood, C.; Kozlowski, J. M.; Figg, W. D.; Sampson, M. L.; Elin, R. J.; Samid, D. The Differentiating Agent PhenylAcetate Increases Prostate-Specific Antigen Production by Prostate Cancer Cells. Prostate 1996, 29, 177-182.